Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.
Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451) / E. Tremoli, G. Morazzoni, P. Maderna, S. Colli, R. Paoletti. - In: THROMBOSIS RESEARCH. - ISSN 0049-3848. - 23:6(1981 Sep 15), pp. 549-553.
Titolo: | Studies on the antithrombotic action of BOC-D-PHE-PRO-ARG-H (GYKI 14,451) |
Autori: | TREMOLI, ELENA (Primo) COLLI, SUSANNA (Penultimo) PAOLETTI, RODOLFO (Ultimo) |
Parole Chiave: | Experimental venous thrombosis; Thrombin inhibitors |
Settore Scientifico Disciplinare: | Settore BIO/14 - Farmacologia |
Data di pubblicazione: | 15-set-1981 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/0049-3848(81)90178-X |
Appare nelle tipologie: | 01 - Articolo su periodico |